Give Online: Help shape patient care for generations to come.
Cleveland Clinic Logo

Appointments

Request an Appointment

Cancer Answer Line:
866.223.8100

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

IRBCCTitleHospitalStagePhaseDisease
07-267  Collection of Blood and Tissue from Patients with Upper Aerodigestive Malignancies for Research Purposes (The UAM Tissue Resource) Main Campus  Esophageal, Head & Neck, Lung, Mesothelioma, Thyroid
A08110514-1418 Randomized double blind placebo controlled study of erlotinib or placebo in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) Fairview, Florida Weston, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, South Pointe, Strongsville, Wooster  NSCLC (Non-small cell lung cancer)
A15121614-1419 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) Fairview, Florida Weston, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, South Pointe, Strongsville, Wooster  Lung
ALTR 1614 15-164 A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Squamous Cell Head and Neck Cancer Main Campus Phase 1Head & Neck, Melanoma, NSCLC (Non-small cell lung cancer), Renal, Solid Tumors
BPS 1510CC928 Randomized Phase 3 Trial of Gemcitabine / Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects with Previously Untreated Stage IV Squamous Non Small Cell Lung Cancer (NSCLC) Main CampusStage 4Phase 3Lung
CHRV 0090  Clinical predictors of benefit from pemetrexed in patients with metastatic non small cell lung cancer Main Campus  Lung
CHRV 0120  Clinical Implications of Routine Testing for Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Nonsquamous Non-small Cell Lung Cancer. Main Campus  Lung
ECOG 451214-1420 A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein Fairview, Florida Weston, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, South Pointe, Strongsville, Wooster Phase 3NSCLC (Non-small cell lung cancer)
KCC 1515 15-978 Phase II study of MK-3475 as Maintenance Therapy in Extensive Stage Small Cell Lung Cancer (SCLC) Patients Fairview, Hillcrest, Main Campus Phase 2Lung, SCLC (Small-Cell Lung Cancer)
NOVA 1515 15-401 A Phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-positive non-small cell lung cancer (NSCLC) metastatic to the brain and/or to leptomeninges Main Campus Phase 2Lung, NSCLC (Non-small cell lung cancer)
NRG BR001 15-695 A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases Main Campus Phase 1Breast, Lung, NSCLC (Non-small cell lung cancer), Prostate
NRG LU001 15-213 Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC Fairview, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, Strongsville, Wooster Phase 2Lung, NSCLC (Non-small cell lung cancer)
PFIZ 1515 15-1041 A Phase 1b study of Crizotinib in combination with Pembrolizumab (MK-3475) in patients with untreated advanced ALK-translocated non-small cell lung cancer Main Campus Phase 1NSCLC (Non-small cell lung cancer)
RTOG 0538CC707 Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide Fairview, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, Strongsville, Wooster Phase 3Lung
RTOG 1106081201C Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Fairview, Hillcrest, Independence, Main Campus, Strongsville, Wooster  Lung
RTOG 130614-577 A Randomized Phase II Study Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer Beachwood, Fairview, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, Strongsville, Wooster Phase 2Lung, NSCLC (Non-small cell lung cancer)
SWOG 140014-894 Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer Beachwood, Fairview, Hillcrest, Independence, Main Campus, Mansfield, North Coast Cancer, South Pointe, Strongsville, Wooster Phase 2, Phase 3Lung
UNC 151212-1096 LCCC 1123: Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients with EGFR Mutation Who Have Previously Progressed on an EGFR-TKI Main CampusStage 4Phase 2Lung
UNC 251213-028 A Phase II, multicenter, single arm study of the tolerability of weekly nab-paclitaxel as second line treatment for elderly patients with advanced lung cancer Main Campus Phase 2Lung
ZNCA 1515 15-1161 A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Main Campus Phase 3NSCLC (Non-small cell lung cancer)

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2016 Cleveland Clinic. All rights reserved.